Resistant Hypertension and Aldosterone: An Update

Canadian Journal of Cardiology

Volumn 28, Issue 3, 2012, Pages 318-325

  Clark, Donald ^a   Ahmed, Mustafa I ^a   Calhoun, David A ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; PERINDOPRIL; RENIN; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BREAST TENDERNESS; DIURETIC THERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; GYNECOMASTIA; HORMONE RECEPTOR INTERACTION; HUMAN; HYPERKALEMIA; HYPERTENSION; PLASMA RENIN ACTIVITY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; REVIEW; SLEEP APNEA SYNDROME;

ALDOSTERONE; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SLEEP APNEA, OBSTRUCTIVE; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84860917505     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.03.010     Document Type: Review

References (63)

1. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510-e526.
2. Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011, 57:1076-1080.
3. Garg J.P., Elliott W.J., Folker A., Izhar M., Black H.R., Service R.U.H. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005, 18(5 pt 1):619-626.
4. de la Sierra A., Segura J., Banegas J.R., et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011, 57:898-902.
5. Dahlöf B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
6. Gupta A.K., Nasothimiou E.G., Chang C.L., et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens 2011, 29:2004-2013.
7. Funder J.W., Carey R.M., Fardella C., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3266-3281.
8. Mihailidou A.S. Nongenomic actions of aldosterone: physiological or pathophysiological role?. Steroids 2006, 71:277-280.
9. Le Moëllic C., Ouvrard-Pascaud A., Capurro C., et al. Early nongenomic events in aldosterone action in renal collecting duct cells: PKCalpha activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. J Am Soc Nephrol 2004, 15:1145-1160.
10. Schiffrin E.L. Effects of aldosterone on the vasculature. Hypertension 2006, 47:312-318.
11. Williams G.H. Cardiovascular benefits of aldosterone receptor antagonists: what about potassium?. Hypertension 2005, 46:265-266.
12. Arima S., Kohagura K., Xu H.L., et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003, 14:2255-2263.
13. Arima S., Kohagura K., Xu H.L., et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 2004, 43:352-357.
14. Schmidt B.M., Oehmer S., Delles C., et al. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 2003, 42:156-160.
15. Nishizaka M.K., Zaman M.A., Green S.A., Renfroe K.Y., Calhoun D.A. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004, 109:2857-2861.
16. Rocha R., Rudolph A.E., Frierdich G.E., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802-H1810.
17. Blasi E.R., Rocha R., Rudolph A.E., Blomme E.A., Polly M.L., McMahon E.G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003, 63:1791-1800.
18. Funder J.W. The nongenomic actions of aldosterone. Endocr Rev 2005, 26:313-321.
19. Büssemaker E., Hillebrand U., Hausberg M., Pavenstädt H., Oberleithner H. Pathogenesis of hypertension: interactions among sodium, potassium, and aldosterone. Am J Kidney Dis 2010, 55:1111-1120.
20. Vasan R.S., Evans J.C., Larson M.G., et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004, 351:33-41.
21. Bernini G., Galetta F., Franzoni F., et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens 2008, 26:2399-2405.
22. Tsuchiya K., Yoshimoto T., Hirata Y. Endothelial dysfunction is related to aldosterone excess and raised blood pressure. Endocr J 2009, 56:553-559.
23. Rossi G.P., Sacchetto A., Visentin P., et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996, 27:1039-1045.
24. Rossi G.P., Bernini G., Desideri G., et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006, 48:232-238.
25. Nishimura M., Uzu T., Fujii T., et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999, 33:261-266.
26. Takeda R., Matsubara T., Miyamori I., Hatakeyama H., Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 1995, 18:370-373.
27. Milliez P., Girerd X., Plouin P.F., Blacher J., Safar M.E., Mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243-1248.
28. Fishman L.M., Küchel O., Liddle G.W., Michelakis A.M., Gordon R.D., Chick W.T. Incidence of primary aldosteronism uncomplicated "essential" hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. JAMA 1968, 205:497-502.
29. Kaplan NM. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Ann Intern Med 967;66:1079-90.
30. Sinclair A.M., Isles C.G., Brown I., Cameron H., Murray G.D., Robertson J.W. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987, 147:1289-1293.
31. Rossi G.P. Diagnosis and treatment of primary aldosteronism. Rev Endocr Metab Disord 2011, 12:27-36.
32. Gordon R.D., Stowasser M., Tunny T.J., Klemm S.A., Rutherford J.C. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315-318.
33. Rossi G.P., Bernini G., Caliumi C., et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293-2300.
34. Mosso L., Carvajal C., González A., et al. Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161-165.
35. Strauch B., Zelinka T., Hampf M., Bernhardt R., Widimsky J. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003, 17:349-352.
36. Gallay B.J., Ahmad S., Xu L., Toivola B., Davidson R.C. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699-705.
37. Calhoun D.A., Nishizaka M.K., Zaman M.A., Thakkar R.B., Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
38. Eide I.K., Torjesen P.A., Drolsum A., Babovic A., Lilledahl N.P. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217-2226.
39. Umpierrez G.E., Cantey P., Smiley D., et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007, 30:1699-1703.
40. Cuspidi C., Macca G., Sampieri L., et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001, 19:2063-2070.
41. Muxfeldt E.S., Bloch K.V., Nogueira A.R., Salles G.F. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit 2003, 8:181-185.
42. Pierdomenico S.D., Lapenna D., Bucci A., et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005, 18:1422-1428.
43. Isaksson H., Ostergren J. Prognosis in therapy-resistant hypertension. J Intern Med 1994, 236:643-649.
44. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16(11 pt 1):925-930.
45. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
46. de Souza F., Muxfeldt E., Fiszman R., Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010, 55:147-152.
47. Alvarez-Alvarez B., Abad-Cardiel M., Fernandez-Cruz A., Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010, 28:2329-2335.
48. Gaddam K., Corros C., Pimenta E., et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 2010, 55:1137-1142.
49. Calhoun D.A., White W.B. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008, 2:462-468.
50. Saha C., Eckert G.J., Ambrosius W.T., et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005, 46:481-487.
51. Pisoni R., Acelajado M.C., Cartmill F.R. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens 2011, [Epub ahead of print].
52. Gaddam K.K., Nishizaka M.K., Pratt-Ubunama M.N., et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008, 168:1159-1164.
53. Ogilvie R.I. The clinical pharmacology section of the International Union of Pharmacology. Clin Pharmacol Ther 1987, 41:365-367.
54. Nieto F.J., Young T.B., Lind B.K., et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000, 283:1829-1836.
55. Peppard P.E., Young T., Palta M., Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000, 342:1378-1384.
56. Logan A.G., Perlikowski S.M., Mente A., et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001, 19:2271-2277.
57. Pratt-Ubunama M.N., Nishizaka M.K., Boedefeld R.L., et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007, 131:453-459.
58. Dernaika T.A., Kinasewitz G.T., Tawk M.M. Effects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apnea. J Clin Sleep Med 2009, 5:103-107.
59. Lozano L., Tovar J.L., Sampol G., et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. J Hypertens 2010, 28:2161-2168.
60. Gonzaga C.C., Gaddam K.K., Ahmed M.I., et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 2010, 6:363-368.
61. Sim J.J., Yan E.H., Liu I.L., et al. Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J Hypertens 2011, 29:1553-1559.
62. Friedman O., Bradley T.D., Chan C.T., Parkes R., Logan A.G. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. Hypertension 2010, 56:1077-1082.
63. Gaddam K., Pimenta E., Thomas S.J., et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 2010, 24:532-537.